Higher-dose Exelon Patch approved for Alzheimer's

Share this article:
Higher-dose Exelon Patch approved for Alzheimer's
Higher-dose Exelon Patch approved for Alzheimer's
The Food and Drug Administration has approved a 13.3mg/24h dosage strength of the Exelon Patch for the treatment of patients with mild to moderate Alzheimer's disease. Approval was based on a 48-week double-blind phase of the OPTIMA study. The controlled trial targeted people with mild to moderate Alzheimer's. Compared to an older patch, patients treated with this higher dosage patch experienced statistically significant functional improvement.
Share this article:

More in Products

LeadingAge's CAST releases EHR matrix selection tool

LeadingAge's Center for Aging Services Technologies released its 2014 version of a tool to let long-term providers choose the best electronic health record for their facility.

New magnetic badges debut

New magnetic badges debut

Imprint Plus has introduced The Mighty Badge name badge kit, which allows users to create reusable but personalized badges.

Hollister Incorporated celebrates antibacterial foam dressing

Hollister Incorporated celebrates antibacterial foam dressing ...

Hollister Incorporated's new Hydrofera Blue Ready antibacterial foam dressing has been named a "Top 10 Innovation in Podiatry" according to the Podiatry Today journal, as well as a "Top Innovation ...